Though artificial bioactive compounds are permitted in lots of nations for meals functions, they’re changing into much less and fewer welcome by customers. Due to this fact, there was an growing curiosity in changing these artificial compounds by pure bioactive compounds. These pure compounds can be utilized as meals components to take care of the meals high quality, meals security and attraction, and as meals dietary supplements or nutraceuticals to right dietary deficiencies, keep an appropriate consumption of vitamins, or to assist physiological capabilities, respectively.
Latest research reveal that quite a few meals wastes, significantly fruit and greens byproducts, are a very good supply of bioactive compounds that may be extracted and reintroduced into the meals chain as pure meals components or in meals matrices for acquiring nutraceuticals and purposeful meals. This evaluation addresses common questions regarding using fruit and greens byproducts as new sources of pure bioactive compounds which can be being addressed to meals as pure components and dietary supplements. These bioactive compounds should observe the authorized necessities and evaluations to evaluate the dangers for human well being and their toxicity should be thought-about earlier than being launched into the market.
To beat the potential well being danger whereas growing the organic exercise, stability and biodistribution of the dietary supplements’ technological options have been studied comparable to encapsulation of bioactive compounds into micro or nanoparticles or nanoemulsions. It will permit enhancing the soundness and launch alongside the gastrointestinal tract in a managed method into the precise tissues. This evaluation summarizes the valorization path {that a} bioactive compound recovered from an agro-food waste can face from the second their potentialities are exhibited till it reaches the ultimate client and the protection and toxicity challenges, they could overcome.
Preclinical Bioavailability, Tissue Distribution, and Protein Binding Research of Erinacine A, a Bioactive Compound from Hericium erinaceus Mycelia Utilizing Validated LC-MS/MS Methodology
Erinacine A, derived from the mycelia of Hericium erinaceus, has attracted a lot consideration because of its neuroprotective properties. Nevertheless, only a few research have been carried out on the bioavailability, tissue distribution, and protein binding of erinacine A. This research aimed to analyze the bioavailability, tissue distribution, and protein binding of erinacine A in Sprague-Dawley rats. After oral administration (po) and intravenous administration (iv) of two.381 g/kg BW of the H. erinaceus mycelia extract (equal to 50 mg/kg BW of erinacine A) and 5 mg/kg BW of erinacine A, respectively, absolutely the bioavailability of erinacine A was estimated as 24.39%.
Erinacine A was detected in mind at 1 h after oral dosing and reached the height at eight h. Protein binding assay confirmed unbound erinacine A fractions in mind to blood ratio is near unity, supporting passive diffusion because the dominating transport. Feces was the foremost route for the elimination of erinacine A. This research is the primary to indicate that erinacine A can penetrate the blood-brain barrier of rats by the technique of passive diffusion and thus assist the event of H. erinaceus mycelia for the development of neurohealth.
Enzymatic pretreatment of seeds is a novel method that enhances the well being advantages of the extracted oil. The research investigated the affect of the enzymatic pretreatment of seeds on the standard of oil from totally different pomegranate cultivars. The standard of the ultrasound-assisted (and ethanol-extracted) oil was studied, with respect to the refractive index (RI), yellowness index (YI), conjugated dienes (Ok232), peroxide worth (PV) ρ-anisidine worth (AV), whole oxidation worth (TOTOX), whole carotenoid content material (TCC), whole phenolic compounds (TPC), fatty acid composition, phytosterol composition, ferric lowering antioxidant energy (FRAP), and a pair of.2-diphenyl-1-picryl hydrazyl (DPPH) radical scavenging capability.
Dedication of Bioactive Compounds in Sequential Extracts of Chia Leaf ( Salvia hispanica L.) Utilizing UHPLC-HRMS (Q-Orbitrap) and a World Analysis of Antioxidant In Vitro Capability
Shoppers’ curiosity in meals which can be nutritionally balanced and with well being advantages has elevated. The meals trade is being attentive to using the ancestral seed Salvia hispanica L., generally often known as chia. At current, solely chia seeds, that are a pure supply of omega-Three and omega-6, fiber, proteins, and pure antioxidants, are commercialized. Though some research reveal the presence of a number of bioactive compounds, comparable to polyphenols (e.g., vitexin, orientin, and a few hydroxycinnamic acids) in chia leaf methanolic extracts, the chia plant is usually used as fertilizer or handled as waste after harvest.
Due to this fact, it might symbolize a by-product that may very well be thought-about an incredible supply of bioactive compounds with unexplored potential in medication and meals trade functions. On this work, UHPLC-HRMS (Q-Orbitrap) was employed to tentatively determine and decide the bioactive compounds current in numerous leaf extracts of chia crops of black and white seed phenotype obtained with solvents of various polarity (ethanol, ethyl acetate, dichloromethane, and hexane) to handle chia plant by-product revalorization. The chemical antioxidant capability was additionally studied and correlated to the discovered bioactive compounds.
C8orf55 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0261504 | ABM | 1.0 ug DNA | EUR 184.8 |
C8orf55 Protein Vector (Human) (pPB-C-His) |
|||
| PV066905 | ABM | 500 ng | EUR 662.4 |
C8orf55 Protein Vector (Human) (pPB-N-His) |
|||
| PV066906 | ABM | 500 ng | EUR 662.4 |
C8orf55 Protein Vector (Human) (pPM-C-HA) |
|||
| PV066907 | ABM | 500 ng | EUR 662.4 |
C8orf55 Protein Vector (Human) (pPM-C-His) |
|||
| PV066908 | ABM | 500 ng | EUR 662.4 |
C8orf55 3'UTR Luciferase Stable Cell Line |
|||
| TU002535 | ABM | 1.0 ml | EUR 1672.8 |
C8orf55 3'UTR GFP Stable Cell Line |
|||
| TU052535 | ABM | 1.0 ml | EUR 1672.8 |
C8orf55 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0261505 | ABM | 3 x 1.0 ug | EUR 451.2 |
C8orf55 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0261506 | ABM | 1.0 ug DNA | EUR 200.4 |
C8orf55 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0261507 | ABM | 1.0 ug DNA | EUR 200.4 |
C8orf55 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0261508 | ABM | 1.0 ug DNA | EUR 200.4 |
Positive control tissue section for each individua |
|||
| Control-Slides-for-each-antibody | Innovex | Set of 25 | EUR 355 |
|
Description: Positive control tissue section for each individual antibody; Based on availability; INQUIRE |
|||
CD11b Antibody Antibody |
|||
| ABD2911 | Lifescience Market | 100 ug | EUR 525.6 |
ASAP1 antibody Antibody |
|||
| DF8746 | Affbiotech | 200ul | EUR 420 |
anti- Antibody^Polyclonal antibody control antibody |
|||
| LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Antibody |
|||
| A1360-500 | Biovision | each | Ask for price |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| 20-abx004855 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx008109 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx123734 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx014333 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-400ul | Abbexa | 400 ul | EUR 627.6 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-80l | Abbexa | 80 µl | EUR 343.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx036399-100ug | Abbexa | 100 ug | EUR 469.2 |
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319900 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319901 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319905 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319913 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx230204-100ug | Abbexa | 100 ug | EUR 577.2 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx324434 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx311665 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx234901-100ug | Abbexa | 100 ug | EUR 661.2 |
Anti-Anti-SEPT6 antibody antibody |
|||
| STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
|||
Anti-Anti-SEPT9 Antibody antibody |
|||
| STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
|||
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ111530 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT4 Antibody antibody |
|||
| STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
|||
Anti-Anti-MARCH9 Antibody antibody |
|||
| STJ112609 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ113941 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ114081 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-MARCH8 Antibody antibody |
|||
| STJ114828 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ116214 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ117206 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT12 Antibody antibody |
|||
| STJ117759 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118549 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118550 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH7 Antibody antibody |
|||
| STJ118752 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT3 Antibody antibody |
|||
| STJ118990 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ28365 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ28963 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ25475 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ25477 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ25479 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT1 antibody antibody |
|||
| STJ119580 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
|||
CLCN5 Antibody / CIC-5 antibody |
|||
| RQ6462 | NSJ Bioreagents | 100ug | EUR 419 |
|
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
|||
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-100ul | SAB | 100ul | EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-50ul | SAB | 50ul | EUR 286.8 |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: anti-CD22 monoclonal antibody |
|||
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: anti-CD22 monoclonal antibody |
|||
Antibody Pair to ApoA-V antibody |
|||
| 10R-1876 | Fitzgerald | 100 ul | EUR 781.2 |
|
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
|||
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103034 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103035 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103036 | Abbexa |
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
|||
| abx023924-1mg | Abbexa | 1 mg | EUR 1446 |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319902 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319903 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319904 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319906 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319907 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319908 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319914 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319915 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319916 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319929 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319930 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319931 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
|||
| 20-abx311666 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
|||
| 20-abx311667 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
|||
| 20-abx311668 | Abbexa |
|
|
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
|||
| abx233571-100ug | Abbexa | 100 ug | EUR 577.2 |
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
|||
| abx411057-50ug | Abbexa | 50 ug | EUR 710.4 |
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
|||
| AMM06679G | Leading Biology | 0.05mg | EUR 633.6 |
|
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
|||
Goat anti- human Antibody^Polyclonal antibody |
|||
| LSMab09896 | Lifescience Market | 100 ug | EUR 525.6 |
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D | Stressmarq | 0.1mg | EUR 424.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A390 | Stressmarq | 0.1mg | EUR 481.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A488 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A565 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A594 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A633 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A655 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A680 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A700 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-ALP | Stressmarq | 0.1mg | EUR 472.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-APC | Stressmarq | 0.1mg | EUR 478.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC . |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-APCCY7 | Stressmarq | 0.1mg | EUR 565.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-BI | Stressmarq | 0.1mg | EUR 475.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY350 | Stressmarq | 0.1mg | EUR 496.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY405 | Stressmarq | 0.1mg | EUR 483.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY488 | Stressmarq | 0.1mg | EUR 471.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY594 | Stressmarq | 0.1mg | EUR 474 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-DY633 | Stressmarq | 0.1mg | EUR 468 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-FITC | Stressmarq | 0.1mg | EUR 470.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-HRP | Stressmarq | 0.1mg | EUR 465.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-P594 | Stressmarq | 0.1mg | EUR 488.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-PCP | Stressmarq | 0.1mg | EUR 478.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-RPE | Stressmarq | 0.1mg | EUR 476.4 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE . |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-STR | Stressmarq | 0.1mg | EUR 477.6 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692S | Stressmarq | 0.012mg | EUR 78 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
|||
Anti-Noelin Antibody BIOTIN Antibody BIOTIN |
|||
| STJ501938 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
| STJ501939 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody BIOTIN Antibody BIOTIN |
|||
| STJ501940 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
| STJ501941 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-IgG1 Negative Control Antibody antibody |
|||
| STJ16100881 | St John's Laboratory | 1 mL | EUR 573.6 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20161-100UG | NSJ Bioreagents | 100ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20161BTN-50UG | NSJ Bioreagents | 50ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20161SAF-250UG | NSJ Bioreagents | 250ug | EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20179-100UG | NSJ Bioreagents | 100ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20179BTN-50UG | NSJ Bioreagents | 50ug | EUR 409 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| R20179SAF-250UG | NSJ Bioreagents | 250ug | EUR 979 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| RQ4975 | NSJ Bioreagents | 100ul | EUR 419 |
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V9032-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V9032-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V9032IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V9032SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151CF488-100T | NSJ Bioreagents | 100 Tests | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3151SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3152-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3152-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3152SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3261-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3261-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3261SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3262-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3262-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V3262SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V2151-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V2151-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V2151SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V2153-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V2153-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V2153CF488-100T | NSJ Bioreagents | 100 Tests | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V2153IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V2153SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7875-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7875-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7875SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7878-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7878-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7878SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7879-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7879-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Lambda Light Chain Antibody / Lambda Antibody |
|||
| V7879SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
|||
Aggrecan antibody |
|||
| 61-1049 | Fitzgerald | 250 ug | EUR 457.2 |
|
Description: Mouse Monoclonal Aggrecan antibody (Biotin) |
|||
Calcitonin antibody |
|||
| 61-1050 | Fitzgerald | 500 ug | EUR 600 |
|
Description: Mouse Monoclonal Calcitonin antibody (Biotin) |
|||
HCG antibody |
|||
| 61-1052 | Fitzgerald | 500 ug | EUR 457.2 |
|
Description: Mouse Monoclonal HCG antibody (Biotin) |
|||
Osteocalcin antibody |
|||
| 61-1056 | Fitzgerald | 250 ug | EUR 457.2 |
|
Description: Mouse Monoclonal Osteocalcin antibody (Biotin) |
|||
ZIP12 Antibody |
|||
| 6101-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZIP12 Antibody: The zinc transporter ZIP12, also known as SLC39A12, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP12 is a multipass membrane protein that belongs to the ZIP transporter subfamily LIV-1. Increased levels of ZIP12 have been observed during acute inflammation in the airway and asthma, suggesting that it may be promote increased zinc uptake, as this can reduce inflammation. The zinc content in brains in individuals with schizophrenia is lower than in individuals with other cerebral diseases, and mutations in ZIP12 have been observed in a small group of schizophrenic patients, suggesting that ZIP12 may play a role in this disease. |
|||
ZIP12 Antibody |
|||
| 6101-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZIP12 Antibody: The zinc transporter ZIP12, also known as SLC39A12, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP12 is a multipass membrane protein that belongs to the ZIP transporter subfamily LIV-1. Increased levels of ZIP12 have been observed during acute inflammation in the airway and asthma, suggesting that it may be promote increased zinc uptake, as this can reduce inflammation. The zinc content in brains in individuals with schizophrenia is lower than in individuals with other cerebral diseases, and mutations in ZIP12 have been observed in a small group of schizophrenic patients, suggesting that ZIP12 may play a role in this disease. |
|||
ZIP13 Antibody |
|||
| 6103-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZIP13 Antibody: The zinc transporter ZIP13, also known as SLC39A13, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP13 is a multipass membrane protein that belongs to the ZIP transporter subfamily LIV-1. Mutations in ZIP13 have recently been shown to cause a spondylocheiro dysplastic form of Ehlers-Danlos syndrome (SCD-EDS), a generalized skeletal dysplasia involving mainly the spine with clinical abnormalities of the hands in addition to EDS-like features. Other experiments have shown that ZIP13 is required for proper connective tissue development and is involved in BMP/TGF- signaling pathways. |
|||
ZIP13 Antibody |
|||
| 6103-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZIP13 Antibody: The zinc transporter ZIP13, also known as SLC39A13, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP13 is a multipass membrane protein that belongs to the ZIP transporter subfamily LIV-1. Mutations in ZIP13 have recently been shown to cause a spondylocheiro dysplastic form of Ehlers-Danlos syndrome (SCD-EDS), a generalized skeletal dysplasia involving mainly the spine with clinical abnormalities of the hands in addition to EDS-like features. Other experiments have shown that ZIP13 is required for proper connective tissue development and is involved in BMP/TGF- signaling pathways. |
|||
ZIP14 Antibody |
|||
| 6105-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZIP14 Antibody: The zinc transporter ZIP14, also known as SLC39A14, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP14 is a glycosylated multipass plasma membrane protein that belongs to the ZIP transporter subfamily LIV-1. ZIP14 has been shown to contribute to the hypozincemia of inflammation and infection and is regulated in the liver by IL-6. In addition to zinc, ZIP14 is also involved in the cellular uptake of non-transferrin-bound iron as well as iron bound to transferrin. |
|||
ZIP14 Antibody |
|||
| 6105-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZIP14 Antibody: The zinc transporter ZIP14, also known as SLC39A14, is a member of a family of divalent ion transporters. Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation. The zinc transporter family is divided into four subfamilies (I, II, LIV-1 and gufA). ZIP14 is a glycosylated multipass plasma membrane protein that belongs to the ZIP transporter subfamily LIV-1. ZIP14 has been shown to contribute to the hypozincemia of inflammation and infection and is regulated in the liver by IL-6. In addition to zinc, ZIP14 is also involved in the cellular uptake of non-transferrin-bound iron as well as iron bound to transferrin. |
|||
KLOTHO Antibody |
|||
| 6107-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: KLOTHO Antibody: KLOTHO is the systemic anti-aging hormone within the glycosidase1 superfamily. It encodes a type I membrane protein that is abundant in the kidney and brain. In mice, a deficiency in KLOTHO expression leads to various systemic phenotypes resembling human aging such as arteriosclerosis, osteoporosis, and skin atrophy together with growth retardation, short life-span and infertility. Transgenic mice overexpressing KLOTHO have an extended life span by inhibiting insulin/IGF1 signaling. KLOTHO is involved in the regulation of calcium/phosphorus homeostasis by inhibiting the synthesis of active vitamin D and identified as a potential tumor suppressor. |
|||
KLOTHO Antibody |
|||
| 6107-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: KLOTHO Antibody: KLOTHO is the systemic anti-aging hormone within the glycosidase1 superfamily. It encodes a type I membrane protein that is abundant in the kidney and brain. In mice, a deficiency in KLOTHO expression leads to various systemic phenotypes resembling human aging such as arteriosclerosis, osteoporosis, and skin atrophy together with growth retardation, short life-span and infertility. Transgenic mice overexpressing KLOTHO have an extended life span by inhibiting insulin/IGF1 signaling. KLOTHO is involved in the regulation of calcium/phosphorus homeostasis by inhibiting the synthesis of active vitamin D and identified as a potential tumor suppressor. |
|||
REQUIEM Antibody |
|||
| 6109-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: REQUIEM Antibody: Requiem is a member of the d4 domain family, characterized by a zinc finger-like structural motif. This protein functions as a transcription factor which is necessary for the apoptotic response following deprivation of survival factors. It is expressed in numerous tissues in both cytosolic and nuclear regions and likely serves a regulatory role in rapid hematopoietic cell growth and turnover. Requiem has been found to act as an adaptor protein that links the NF-κB and SWI/SNF chromatin remodeling factor and is considered a candidate gene for multiple endocrine neoplasia type I, an inherited cancer syndrome involving multiple parathyroid, enteropancreatic, and pituitary tumors. |
|||
REQUIEM Antibody |
|||
| 6109-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: REQUIEM Antibody: Requiem is a member of the d4 domain family, characterized by a zinc finger-like structural motif. This protein functions as a transcription factor which is necessary for the apoptotic response following deprivation of survival factors. It is expressed in numerous tissues in both cytosolic and nuclear regions and likely serves a regulatory role in rapid hematopoietic cell growth and turnover. Requiem has been found to act as an adaptor protein that links the NF-κB and SWI/SNF chromatin remodeling factor and is considered a candidate gene for multiple endocrine neoplasia type I, an inherited cancer syndrome involving multiple parathyroid, enteropancreatic, and pituitary tumors. |
|||
CXXC5 Antibody |
|||
| 6111-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: CXXC5 Antibody: CXXC5 is zinc finger protein closely related to the DVL1-binding protein CXXC4 (also known as Idax), and like CXXC4 is thought to modulate the Wnt signaling pathway during development. CXXC5 is upregulated in neural stem cells upon BMP4 stimulation, leading to decreased levels of the Wnt-signaling target AXIN2 and facilitated the response of the stem cells to Wnt3a. Recent reports suggest CXXC5 transcription is activated by the Wilms tumor 1 (WT1) transcription factor, and together are involved in the WNT/beta-catenin pathway and play a role in embryonic kidney development. |
|||
CXXC5 Antibody |
|||
| 6111-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: CXXC5 Antibody: CXXC5 is zinc finger protein closely related to the DVL1-binding protein CXXC4 (also known as Idax), and like CXXC4 is thought to modulate the Wnt signaling pathway during development. CXXC5 is upregulated in neural stem cells upon BMP4 stimulation, leading to decreased levels of the Wnt-signaling target AXIN2 and facilitated the response of the stem cells to Wnt3a. Recent reports suggest CXXC5 transcription is activated by the Wilms tumor 1 (WT1) transcription factor, and together are involved in the WNT/beta-catenin pathway and play a role in embryonic kidney development. |
|||
TFF3 Antibody |
|||
| 6113-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: TFF3 Antibody: Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. Trefoil peptides contain three intrachain disulfide bonds, forming the trefoil motif, or P-domain and clustered in human chromosome 21q22.3. Trefoil Factor 3 (TFF3) is one of three trefoil peptides secreted by epithelial cells that line mucus membranes in the large and small intestines and lower respiratory tract. TFF3 is mainly active as a disulfide-linked homodimer and may have a role in promoting cell migration in healing processes. It is involved in the maintenance and repair of the intestinal mucosa. |
|||
TFF3 Antibody |
|||
| 6113-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: TFF3 Antibody: Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. Trefoil peptides contain three intrachain disulfide bonds, forming the trefoil motif, or P-domain and clustered in human chromosome 21q22.3. Trefoil Factor 3 (TFF3) is one of three trefoil peptides secreted by epithelial cells that line mucus membranes in the large and small intestines and lower respiratory tract. TFF3 is mainly active as a disulfide-linked homodimer and may have a role in promoting cell migration in healing processes. It is involved in the maintenance and repair of the intestinal mucosa. |
|||
WIZ Antibody |
|||
| 6117-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: WIZ Antibody: WIZ, also known as ZNF803, was initially identified in a mouse cerebellum cDNA library screen and its message was found to be expressed in the granule cell layers of the cerebellum as well as in the dentate gyrus and olfactory bulb. Later analysis indicates however that WIZ is ubiquitously expressed. WIZ is a nuclear protein that co-localizes with G9a, a histone methyltransferase responsible for mono- and dimethylation of H3K9 at euchromatic regions. WIZ can also associate with CtBP family proteins, known to be transcriptional co-repressors, and has been suggested to link G9a/GLP complexes to the CtBP co-repressor machinery, possibly regulating complex stability and gene silencing. |
|||
WIZ Antibody |
|||
| 6117-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: WIZ Antibody: WIZ, also known as ZNF803, was initially identified in a mouse cerebellum cDNA library screen and its message was found to be expressed in the granule cell layers of the cerebellum as well as in the dentate gyrus and olfactory bulb. Later analysis indicates however that WIZ is ubiquitously expressed. WIZ is a nuclear protein that co-localizes with G9a, a histone methyltransferase responsible for mono- and dimethylation of H3K9 at euchromatic regions. WIZ can also associate with CtBP family proteins, known to be transcriptional co-repressors, and has been suggested to link G9a/GLP complexes to the CtBP co-repressor machinery, possibly regulating complex stability and gene silencing. |
|||
ZBTB3 Antibody |
|||
| 6119-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZBTB3 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. While little is known about ZBTB3, the related protein ZBTB2 is thought to be phosphorylated in response to the DNA damage, probably by either ATM or ATR. Other ZBTB proteins, such as ZBTB4 and ZBTB38 bind methylated DNA and repress transcription, suggesting that ZBTB3 may also act as a transcription repressor. |
|||
ZBTB3 Antibody |
|||
| 6119-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZBTB3 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. While little is known about ZBTB3, the related protein ZBTB2 is thought to be phosphorylated in response to the DNA damage, probably by either ATM or ATR. Other ZBTB proteins, such as ZBTB4 and ZBTB38 bind methylated DNA and repress transcription, suggesting that ZBTB3 may also act as a transcription repressor. |
|||
ZBTB4 Antibody |
|||
| 6121-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZBTB4 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. Similar to Kaiso, a zinc-finger containing protein that can bind methylated CpGs, ZBTB4 can also bind methylated DNA and repress transcription. ZBTB4 has been shown to associate with the Sin3/histone deacetylase co-repressor and repress expression of P21CIP1 as part of a heterodimeric complex with Miz1. In cultured cells, depletion of ZBTB4 promotes cell cycle arrest in response to p53 activation and suppresses apoptosis through regulation of P21CIP1, suggesting that ZBTB4 is a critical determinant of the cellular response to p53 activation. HIPK2, a kinase that is involved in cellular proliferation and survival, phosphorylates and down-regulates ZBTB4 under normal cell growth conditions; this degradation increases with DNA damage. |
|||
ZBTB4 Antibody |
|||
| 6121-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZBTB4 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. Similar to Kaiso, a zinc-finger containing protein that can bind methylated CpGs, ZBTB4 can also bind methylated DNA and repress transcription. ZBTB4 has been shown to associate with the Sin3/histone deacetylase co-repressor and repress expression of P21CIP1 as part of a heterodimeric complex with Miz1. In cultured cells, depletion of ZBTB4 promotes cell cycle arrest in response to p53 activation and suppresses apoptosis through regulation of P21CIP1, suggesting that ZBTB4 is a critical determinant of the cellular response to p53 activation. HIPK2, a kinase that is involved in cellular proliferation and survival, phosphorylates and down-regulates ZBTB4 under normal cell growth conditions; this degradation increases with DNA damage. |
|||
ZBTB5 Antibody |
|||
| 6123-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZBTB5 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB5 was identified though sequence analysis as a POZ domain Kruppel-like zinc finger (POK) protein. Further experiments indicated that it binds DNA and can directly repress transcription of the cell cycle arrest gene p21. ZBTB5 can also interact with co-repressor histone deacetylase complexes such as BCoR, NCoR, and SMRT via its POZ domain, resulting in deacetylation of histones Ac-H3 and Ac-H4 at the proximal promoter. ZBTB5 stimulates both cell proliferation and cell cycle progression, suggesting that it may act as a potential proto-oncogene. |
|||
ZBTB5 Antibody |
|||
| 6123-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZBTB5 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB5 was identified though sequence analysis as a POZ domain Kruppel-like zinc finger (POK) protein. Further experiments indicated that it binds DNA and can directly repress transcription of the cell cycle arrest gene p21. ZBTB5 can also interact with co-repressor histone deacetylase complexes such as BCoR, NCoR, and SMRT via its POZ domain, resulting in deacetylation of histones Ac-H3 and Ac-H4 at the proximal promoter. ZBTB5 stimulates both cell proliferation and cell cycle progression, suggesting that it may act as a potential proto-oncogene. |
|||
ZBTB6 Antibody |
|||
| 6125-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZBTB6 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB6, also known as ZNF482, is highly expressed in brain. While little is known about ZBTB6, other ZBTB proteins, such as ZBTB4 bind methylated DNA and repress transcription. Another ZBTB family member, ZBTB5, also acts as a transcriptional repressor, and can interact with co-repressor histone deacetylase complexes such as BCoR, NCoR, and SMRT via its POZ domain, suggesting that ZBTB6 may also act as a transcriptional repressor. |
|||
ZBTB6 Antibody |
|||
| 6125-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZBTB6 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB6, also known as ZNF482, is highly expressed in brain. While little is known about ZBTB6, other ZBTB proteins, such as ZBTB4 bind methylated DNA and repress transcription. Another ZBTB family member, ZBTB5, also acts as a transcriptional repressor, and can interact with co-repressor histone deacetylase complexes such as BCoR, NCoR, and SMRT via its POZ domain, suggesting that ZBTB6 may also act as a transcriptional repressor. |
|||
ZBTB7A Antibody |
|||
| 6127-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZBTB7A Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB7A, also known as LRF, was initially identified as a potential target of the LAZ-3/BCL-6 oncogene. Later reports demonstrated that it could bind to the wild-type IST (inducer of short transcripts) elements of HIV-1 long terminal repeats (LTRs) and stimulate Tat activity on the HIV-1 LTR. More recently it ZBTB7A has been recognized as a proto-oncogene whose overexpression contributes to malignancy in breast cancer and functions as a co-repressor of the androgen receptor in prostate cancer cells. |
|||
ZBTB7A Antibody |
|||
| 6127-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZBTB7A Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB7A, also known as LRF, was initially identified as a potential target of the LAZ-3/BCL-6 oncogene. Later reports demonstrated that it could bind to the wild-type IST (inducer of short transcripts) elements of HIV-1 long terminal repeats (LTRs) and stimulate Tat activity on the HIV-1 LTR. More recently it ZBTB7A has been recognized as a proto-oncogene whose overexpression contributes to malignancy in breast cancer and functions as a co-repressor of the androgen receptor in prostate cancer cells. |
|||
ZBTB8 Antibody |
|||
| 6129-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: ZBTB8 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB8, also known as BOZ-F1, is present in multiple tissues, and is highly expressed in the cytoplasm of the placenta. While little is known about ZBTB8, other ZBTB proteins, such as ZBTB4 bind methylated DNA and repress transcription. Another ZBTB proteins, ZBTB7A, has been implicated as a proto-oncogene whose overexpression contributes to malignancy in breast cancer, suggesting that ZBTB8 may act as a transcriptional repressor or be involved in tumorigenesis. |
|||
ZBTB8 Antibody |
|||
| 6129-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: ZBTB8 Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB8, also known as BOZ-F1, is present in multiple tissues, and is highly expressed in the cytoplasm of the placenta. While little is known about ZBTB8, other ZBTB proteins, such as ZBTB4 bind methylated DNA and repress transcription. Another ZBTB proteins, ZBTB7A, has been implicated as a proto-oncogene whose overexpression contributes to malignancy in breast cancer, suggesting that ZBTB8 may act as a transcriptional repressor or be involved in tumorigenesis. |
|||
In these experiments, black chia confirmed the next antioxidant capability than white chia within the ethanolic extracts. Furthermore, experiments on mobile antioxidant exercise have been additionally carried out with a predominance of the white chia extract. It’s famous that the mobile antioxidant exercise outcomes make chia ethanolic extracts promising antioxidants.